Navigation Links
Chiltern Wins Top Prize
Date:3/5/2008

LONDON, March 5 /PRNewswire/ -- Chiltern, a leading global research organization, is proud to announce that it won 4 'Pharmas' at the PharmaTimes Clinical Researcher of the Year ceremony, including the coveted Clinical Department of the Year.

Chiltern received the following awards:

Gold: Clinical Department of the Year - Chiltern International

Gold: Anne Tebbatt in the Project Manager category

Gold: Kara Tanabe in Clinical Research Associate category

Silver: Donna Sexton in Clinical Research Associate category

"We are delighted that these four awards, at such a high profile and well recognized industry event, recognize Chiltern's strengths in both the Global Clinical Development and the Resourcing Solutions models," commented Linda Christmas, Executive Vice President Resourcing Solutions, who accepted the Clinical Department of the Year award for Chiltern. This award recognizes the best overall performance by a company combining all categories and is an outstanding achievement.

The PharmaTimes Clinical Researcher of the Year competition is designed to recognize and reward excellence in pharmaceutical clinical development across Europe. Unlike other awards, these measure individual competence in an exposed environment where finalists go through several preliminary rounds culminating in presentations to seasoned and senior industry managers.

In total Chiltern had four finalists in the individual categories all of whom started with Chiltern as trainees and most of whom have worked both in house and on assignments in sponsors' offices. This lays testament to the excellent training and opportunities offered by the company to its staff, both within the CRO and Resourcing Solutions service offerings.

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience of running and staffing international Phase I to Phase IV clinical trials a
'/>"/>

SOURCE Chiltern
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Marco Romano, MD Joins Chiltern as Medical Director, Europe
2. Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
3. Chiltern Announces Acquisition of an Independent USA Based Clinical Research Organization, Clinical Trial Management Services, Inc.
4. Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam
5. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
6. Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
7. 2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki
8. Prize for Cutting-Edge Laser Innovations
9. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
10. Two more American Cancer Society researchers win Nobel Prize
11. Nobel Honors 3 Former March of Dimes Prize Recipients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...uld boost self-esteem, researchers say , ...ldren are more likely to have handwriting problems...thout autism, researchers say. , The new study ...udy participants had autism spectrum disorder, but...e for perceptual reasoning on an IQ test. , The...
(Date:11/9/2009)...ned sexual function, study says, , , ...e able to restore sexual function to rabbits with ...e lab and implanting it, a new study reports. ,...hers say the technique could one day be used to tr...ere able to show the tissue was able to integrate ...
(Date:11/9/2009)...ire-FirstCall/ - Hard To Treat Diseases (HTDS.PK) ...is, a US$41 billion international healthcare compa...e partner, Zhejiang Tianyuan Bio-Pharmaceutical Co...nd will begin a five-year, $1 billion China initia...increase its investment in its China R&D facil...
(Date:11/9/2009)... be too late when it comes to preventing or improv...Inc. (Take Off Pounds Sensibly), the nonprofit wei... (Vocus) November 9, 2009 -- Tomorrow may b...g a diabetes condition, according to TOPS Club, In...t-loss support organization., , ,Diabetes is a dis...
(Date:11/9/2009)...ghlights positive influence of sports participatio...nt, IL (Vocus) November 9, 2009 -- As people age f...t research has highlighted the importance of exerc...issues. However, a new study published in the Nove...iplinary Approach reveals that there may be signi...
Breaking Medicine News(10 mins):Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2
... city to live in for springtime sufferers, , ...le, Ky., is the most challenging place to live for...thma and Allergy Foundation of America,s 2009 list... with allergies. The rankings are published annual...
...ferent accents every day. Even when a speaker of a...y than we do, we are typically able to recognize t... Laboratories, University of Western Sydney, along...l, which they term "phonological constancy." , In...
...ge from $1.5 Million - $3 Million , , PRINCETON, ...ard: DSCI), a manufacturer and marketer of advance...ed a new contract to supply private label adhesive...lion for Derma Sciences. Shipments to the custome...
...ic alliance has formed in the global battle agains...rass-roots movement Susan G. Komen for the Cure gi...st Cancer Conference, co-organized by the Breast I...fit funds for the fight against breast cancer. To ...
...cognized Nationally - , , WASHINGTON, May 6 /PR...field, Ind., has been named the National Youth Adv... Kids for her leadership in the fight against toba...w.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) ...
...A, May 6 Physicians, Choice, a medical billing se...et, has successfully implemented InstaMed,s singl...includes both payment and clearinghouse solutions....ering new value to the revenue cycle by accelerati...
Other Medicine News:Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 2Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 3Health News:Transatlantic alliance supports breast cancer research 2Health News:Campaign for Tobacco-Free Kids Honors Emily Kile, Greenfield, IN, as National Youth Advocate of the Year 2Health News:Physicians' Choice Leverages InstaMed's Integrated Platform for Healthcare Payment & Clearinghouse Solutions 2Health News:Physicians' Choice Leverages InstaMed's Integrated Platform for Healthcare Payment & Clearinghouse Solutions 3
(Date:11/9/2009)..., Pa., Nov. 9 ARmark Authenticatio...today an alliance in the development and introduct...ntication technology that incorporates microscopic... coatings of solid oral dosage forms (SODFs) to pr...on exclusive rights to market ARmark,s micro-tags ...
(Date:11/9/2009)... Oregon, November 9 Bend Research ...nce in applying innovative pharmaceutical,technolo...ientific and,technical problems, announced today t...x Pharmaceuticals Incorporated, a global biotechno..., Through this new collaboration, Vertex will ...
(Date:11/9/2009)...ov. 9 PAREXEL Internatio... biopharmaceutical services provider, today announ...lities for early phase clinical development throug... manufactures and distributes electrocardiogram (E...XEL is using Mortara Instrument,s Surveyor Telemet...
Breaking Medicine Technology:ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 2ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 3Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 2PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 4PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 5Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results 13493 1Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results 13493 2Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly 242 Billion in 2018 13490 1Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly 242 Billion in 2018 13490 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 1BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 4
...al Meeting -, - Conference call to be hosted toda..., Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRG...ng Phase II,trial of CR011-vcMMAE, an antibody-dru...of patients with unresectable Stage III or Stage I...ator, and Professor and Chairman of,the Department...
...ented at AASLD annual meeting, Pivotal Phase III ...ose,who failed prior treatment, SAN FRANCISCO, No...day reported that a planned interim analysis of a,...gational oral hepatitis C,protease inhibitor, in c...ly increased sustained virologic response (SVR) ra...
Other Medicine Technology:CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10
...gulation (ECP) is a surgical approach to glaucoma ...lized laser application. The ciliary body (which p...from the anterior or posterior segment, through th...asily and accurately identified utilizing endoscop...
Moore Hyperopic Flap Conformer, 48 Diopter
...gulation (ECP) is a surgical approach to glaucoma ...lized laser application. The ciliary body (which p...from the anterior or posterior segment, through th...asily and accurately identified utilizing endoscop...
...gulation (ECP) is a surgical approach to glaucoma ...lized laser application. The ciliary body (which p...from the anterior or posterior segment, through th...asily and accurately identified utilizing endoscop...
Medicine Products: